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Neurological soft signs (NSS) comprise subtle deficits in sensory integration, motor coor-
dination, and sequencing of complex motor acts, which are typically observed in the major-
ity of schizophrenia patients, including chronic cases and neuroleptic-naïve first-episode
patients. However, recent studies clearly demonstrate that NSS are not a static feature of
schizophrenia but vary in the clinical course of the disorder. This effect was investigated
in a meta-analysis based on 17 longitudinal studies published between 1992 and 2012.
Studies included between 10 and 93 patients with schizophrenia spectrum disorders (total
number 787) with follow-up periods between 2 and 208 weeks. Beside the Neurological
Examination Scale, the Cambridge Neurological Inventory and the Heidelberg NSS Scale
were used to assess NSS. All but three studies found NSS to decrease in parallel with
remission of psychopathological symptoms. This effect was more pronounced in patients
with a remitting compared to a non-remitting, chronic course (Cohen’s d 0.81 vs. 0.15) and
was significantly correlated with length of the follow-up period (r =−0.64) but not with
age (r =0.28). NSS scores did not decrease to the level typically observed in healthy con-
trols. From a clinical perspective, NSS may therefore be used to identify subjects at risk to
develop schizophrenia and to monitor disease progression.
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INTRODUCTION
Neurological soft signs (NSS) refer to subtle neurological abnor-
malities comprising deficits in sensory integration, motor coor-
dination, and sequencing of complex motor acts (1–3). It is
generally accepted that NSS are more prevalent in schizophre-
nia patients compared to healthy subjects. They have consistently
been demonstrated in neuroleptic-naïve first-episode patients, i.e.,
prior to medication exposure, supporting the assumption that NSS
constitute an intrinsic feature of schizophrenia. This notion is
underlined by increased NSS scores in high-risk subjects, such as
relatives of schizophrenic patients, or in the unaffected co-twins
of monozygotic twin-pairs discordant for schizophrenia (4–6).
Already in 1980, Torrey found NSS to be associated with more
chronic and severe forms of the illness (7). Along these lines, Man-
schreck and Ames (1) reported significant correlations between
NSS and psychopathological symptoms in a cross-sectional study.
These findings led to the hypothesis that NSS are not a static
feature of schizophrenia but vary in the clinical course of the dis-
order, which was investigated in the late 1980s and early 1990s
by the Heidelberg group (3, 8). Patients with an acute exacerba-
tion of schizophrenia were investigated on admission, the seventh
day of treatment, and following remission of acute symptoms,
prior to discharge. Results clearly demonstrated a decrease of NSS
scores with remission of psychopathological symptoms. Similarly,
the parallel decrease of NSS and psychopathological symptoms
during neuroleptic treatment was confirmed in drug-naïve first-
episode (FE) patients (9) and during the long-term course up
to 4 years (10–12). When contrasted with healthy controls, NSS
scores obtained in schizophrenia patients remained significantly
higher during follow-up indicating that NSS comprise both state-
and trait-features.
These findings are pivotal to our concept of NSS and indicate
that cerebral sites important for motor and sensory functions are
directly involved in schizophrenia. From a clinical standpoint, NSS
may be used to monitor the disease process or to identify subjects
with an increased liability toward schizophrenia. However, these
conclusions are based on the above observation of the remission of
NSS with psychopathological symptoms during the clinical course.
In the present study, we therefore analyzed the development of NSS
in the course of schizophrenia as it was described in longitudinal
studies. We hypothesized NSS scores to decrease with remission
of psychopathological symptoms and expected this effect to be
more pronounced in patients with a more favorable compared to
a chronic, non-remitting course of disorder.
METHODS
Studies on the longitudinal course of NSS in schizophrenia were
identified by conventional bibliographic search in particular of the
reference list of previous papers (13) and by a pubmed search per-
formed in August 2014 using the keywords:“schizophrenia,”“NSS,”
“course,” “follow-up,” “chronicity.” These procedures yielded 16
relevant publications, which reported the data necessary to calcu-
late effect sizes (Cohen’s d). An additional data set was contributed
on request (14). Studies were published between 1992 and 2012;
they differed with respect to the clinical settings and the rating
instruments used (Table 1). Eleven studies assessed NSS with the
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Table 1 | Overview of studies.
Study Follow-up
(weeks)
Scale N Diagnostic
groups
Mean
age (SD)
Medication NSS t1 NSS t2 Effect
size
Psy.
path t1
Psy.
path t2
Effect
size 2
Bachmann et al. (10) 56 HD, PANSS 39 FE (DSM-IV) 27 (7.7) Clin. Needs 15.7 (7.1) 10.1 (7.9) 0.75 52.4 (25.6) 52 (12.4) 0.02
22 HC 28 (3.8) 4.8 (3.3) 4.6 (3.9) 0.06 * *
18 NR (DSM-IV) * 13.8 (7.2) 13.5 (8.7) 0.04 52.6 (14.9) 63.9 (32.6) −0.48
21 R (DSM-IV) * 17.3 (6.8) 7.2 (5.8) 1.60 51.4 (10) 42.6 (10.8) 0.85
Boks et al. (18) 104 NES, PANSS 29 FE (DSM-IV) 26.9 (6.3) 7.5 (7.1) 8.9 (5.5) −0.22 * * *
Buchanan et al. (19) 10 NES, BPRS 16 CH (DSM-III) 34.1 (6.8) Clozapine 16.2 (5.9) 16.8 (8.2) −0.09 11.4 (5.8) 9.4 (5.2) 0.34
10 15 CH (DSM-III) 34.6 (9.1) Haloperidol 14.5 (6.3) 15.1 (7.5) −0.09 12.6 (5.3) 12.0 (5.1) 0.12
Chen et al. (20) 156 motor CNI 93 FE (DSM-IV) 31.2 (9.6) Haloperidol
imitially
1.87 (2) 1.45 (2.2) 0.2 * * *
68 HC 32 (8.4) * * * * *
Cuesta et al. (21) 26 NES 77 FE (DSM-IV) 30.1 (10) Risperidone or
olanzapine
17.1 (9.4) 9.9 (6.8) 0.89 10.1 (3.5)a 1.6 (2.1) 3.04
SAPS, SANS 30.6 (6.2) * * 8 (5.9)b 4.7 (4.9) 0.61
Emsley et al. (14) 52 NES 15 FE (DSM-IV) 28.1 (8.5) 6.2 (3.57) 5.1 (4.0) 0.3 * * *
Mangot and Sawant (22) 52 NES 40 FE (ICD-10) 35.5 (11.9) 8.5 (7.1) 3.3 (4.1) 0.93 * * *
Mayoral et al. (16) 104 NES 29 FE (DSM-IV) 15.7 (1.6) 23.2 (9.1) 19.2 (9.9) 0.42 * * *
22 HC 15.2 (1.6) 12.2 (6.7) 9.7 (5.2) 0.42 * * *
Mayoral et al. (17) 104 NES, PANSS 69 FE (DSM-IV) 15.5 (1.8) 25.2 (9.6) 19.9 (8.1) 0.6 66.2 (17.9) 58 (23.3) 0.40
80 HC 15.2 (1.9) 11.1 (7.2) 9.2 (5.5) 0.3 * * *
Mittal et al. (23) 6 Quitkin, BPRS 19 SCHIZ (DSM-III-R) 36.3 (5.4) Haloperidol 6.3 (0.9) 5.3 (0.8) 1.18 34.3 (2.1) 22.4 (2.2) 5.53
Prikryl et al. (11) 52 NES, PANSS 92 FE (ICD-10) 25.3 (5.5) * * * *
20 NR * 6.5 (4.1) 4.2 (4.1) 0.56 88.4 (19.9) 84.7 (21.6) 0.18
72 R * 5.3 (5.9) 2.7 (3.4) 0.56 97.6 (22.5) 43.8 (11.1) 3.20
Prikryl et al. (12) 208 NES 68 FE (ICD-10) 22.5 (5) 6.3 (5.1) 6.8 (6.6) −0.09 97 (23.2) 51.5 (19) 2.16
29 NR * 6.6 (4.8) 10.1 (7.6) −0.56 * * *
39 R * 6 (5.4) 4.4 (4.5) 0.32 * * *
Schröder et al. (3) variable HD, BPRS 27 CH (DSM-III) 36 (12.1) Clin. needs 27.8 (9.2) 22.1 (7.1) 0.7 * * *
23 R 28.9 (8.9) 23.5 (8.3) 13 (4.7) 1.61 * * *
Schröder et al. (8) variable HD, BPRS 32 CH and R (DSM-III) 32 (9) Clin. needs 21.3 (8.3) 11.5 (5.7) 1.4 46.1 (7.3) 32.1 (5.7) 2.15
Schröder et al. (9) 4 HD, BPRS 15 FE (DSM-III-R) 29.2 (9.4) Benperidol 16.2 (7.5) 10 (4.7) 1.02 48.1 (6.6) 35.7 (7.7) 1.75
8 R 15.5 (7.2) 9.3 (4.6) 1.05 49.4 (7.8) 32.5 (7.2) 2.25
7 NR 17.0 (8.5) 10.9 (5.0) 0.9 46.7 (5.2) 39.3 (7.4) 1.18
Sevincok and Topaloglu (24) 2 NES, PANSS 10 CH (DSM-IV) 24.5 (*) Olanzapine 19.1 (13.2) 14.7 (12.5) 0.34 78.8 (19.9) 58.0 (13.1) 1.26
Whitty et al. (25) 26 NES, PANSS 79 FE (DSM-IV) 23.4 (*) 15.6 (9.7) 12.5 (7.3) 0.36 83.3 (20.1) 58.4 (15.1) 1.41
HD, Heidelberg NSS Scale; PANSS, Positive and Negative Syndrome Scale; NES, Neurological Evaluation Scale; BPRS, Brief Psychiatric Rating Scale; CNI, Cambridge Neurological Inventory; SAPS, Scale for the
assessment of positive symptoms; SANS, Scale for the assessment of negative symptoms; FE, first-episode psychosis; HC, healthy controls; NR, non-remitters; R, remitters; CH, chronic schizophrenics; SCHIZ,
schizophrenia patients; a, SAPS, b, SANS, *, missing values.
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Neurological Examination Scale (NES) and four with the Hei-
delberg scale (HD). One study used the Cambridge Neurological
Inventory [CNI (15)]. Two studies examined adolescents (16, 17).
The latter results will be discussed separately, since the motor sys-
tem has not entirely maturated at this age. Separate effect sizes
were calculated for NSS and psychopathology before estimating
mean effect sizes for patients with remitting and chronic courses.
RESULTS
Included studies are summarized in Table 1. The number of
patients per study ranged between 10 and 93 (total number 787);
12 studies solely included FE patients, 2 studies focused on ado-
lescents. Patients’ clinical course was characterized as either remit-
ting or non-remitting/chronic in eight studies; in one study only
the diagnosis “schizophrenia” was conveyed. Follow-up periods
ranged between 2 weeks and 4 years. In nine studies, the exami-
nation commenced during the acute psychotic episodes; in four
of those a reexamining after remission of acute symptoms, prior
to discharge, took place. Standardized neuroleptic treatment was
prescribed in five studies, namely high potency butyrophenones
(haloperidol or benperidol), risperidone, or olanzapine.
All but three studies described a decrease of NSS in the clin-
ical course. Eleven studies included an assessment of the clini-
cal course. Patients with remitting symptoms showed a steeper
decrease of NSS scores (mean effect size: Cohen’s d 0.81) than
patients with an unfavorable or chronic course (mean effect size:
Cohen’s d 0.15), who even exhibited an increase in scores. Over-
all, effect sizes (Cohen’s d) ranged between −0.56 (patients with
an unfavorable course) and 1.61 (patients with a remitting course
treated for an acute episode) with an overall mean effect size of
Cohen’s d 0.53. Ratings of psychopathological symptoms paral-
leled the development of NSS scores but were only reported in 11
of the 17 studies. Moreover, data on the distinction between neg-
ative and positive symptom scores were provided by five studies
only (12, 17, 21, 23, 24). In FE patients, as a group, a moder-
ate effect size was present (Cohen’s d 0.42). Similar effect sizes
(Cohen’s d : 0.42–0.60) were reported in adolescent patients with
FE psychosis. Effect sizes were significantly (p< 0.05) correlated
with length of the follow-up period (r =−0.64,p= 0.001) but not
with age (r = 0.28).
DISCUSSION
The present meta-analysis revealed two main findings: (i) a con-
firmation that NSS scores decrease in the clinical course of schizo-
phrenia with remission of psychopathological symptoms; and (ii)
an indication that this effect is more pronounced in patients with a
remitting course than in those with non-remitting schizophrenia.
Despite numerous methodological differences, all but three
studies found decreasing NSS scores during the clinical course
with remission of acute schizophrenia symptoms. Boks et al. (18)
reported NSS to increase in a group of 29 FE patients, who were
investigated 2 years apart (Cohen’s d −0.22). They assigned this
effect to a subgroup of patients with a more severe form of the
disorder or a regression to the mean and stressed the importance
of the relatively small sample size when interpreting their findings.
A marginal increase of NSS scores (Cohen’s d −0.09) in patients
with chronic schizophrenia was also reported by Buchanan and
colleagues (19) in 31 patients who received haloperidol or clozap-
ine for 10 weeks. Jahn et al. (26) identified increasing NSS scores
only in a small subgroup of patients in whom symptoms deteri-
orated. Their study could not be included in our meta-analysis,
because only median values had been documented. Prikryl et al.
(12) systematically followed FE patients for 4 years and found NSS
to marginally increase (Cohen’s d −0.09) when the whole group of
68 patients was considered. This effect, however, was caused by a
subgroup of patients developing chronic schizophrenia (Cohen’s
d −0.56) while NSS in those with a remitting course decreased
(Cohen’s d 0.32). A similar build-up of NSS scores has been
described by Chen et al. (27) in 43 patients with chronic schiz-
ophrenia over the course of 3 years. Their study was not included
here, because total NSS scores had not been provided. Taken
together, effect sizes for the decrease of NSS scores ranged from
Cohen’s d 0.04 to Cohen’s d 1.61 with an average of Cohen’s d 0.64.
The smallest effects were seen in patients with non-remitting schiz-
ophrenia (mean effect size for non-remitting patients: Cohen’s d
0.15) while more pronounced effect sizes were observed in patients
with a remitting course (mean effect size for remitting patients:
Cohen’s d 0.81). However, only eight studies assessed the clini-
cal course while nine just characterized patients as FE or solely
documented DSM diagnoses.
A most interesting question arises from the finding that the
decrease of NSS and the decrease of symptoms parallel each other.
Unfortunately, this relationship could not be analyzed any further
by meta-analytic tools. Both NSS and psychopathology had been
assessed with several different instruments, and symptom scores
were not provided in several publications.
The effect sizes reported in FE studies appeared to be lower
than those found in patients with a remitting and even those with
a chronic course. However, only four of the available FE studies
drew a distinction between remitting and non-remitting patients.
In addition, the exact timing of the first examination after study
intake has to be taken into account. While Prikryl and colleagues
(11, 12) and Schröder et al. (9) examined NSS at or shortly after
admission, i.e., in an acute psychotic state – Bachmann et al. (10)
conducted the first NSS examination after clinical stabilization,
before discharge. This may well have had an impact on the findings
since NSS scores typically show a significant decrease with remis-
sion of the acute symptoms (3, 8). The important meta-analysis of
cross-sectional NSS studies by Chan et al. (28) found effect sizes
of patients vs. controls comparisons to be moderated by duration
of illness. One may hypothesize that NSS continue to improve or
worsen during the course following the first manifestation of the
disease; a hypothesis, which conforms to the above cited studies,
namely the differences, which emerged between patients with a
remitting vs. a non-remitting, chronic course.
The decrease of NSS with clinical stabilization during the course
was more pronounced in patients with a favorable than with a non-
remitting course (3, 9, 10, 11, and 12); therefore, NSS scores could
be identified as course predictors. However, even after remission
of the acute illness, NSS scores remained significantly higher than
in healthy controls. These findings demonstrate that NSS in schiz-
ophrenia are both trait- and state-related. NSS persistence and
deterioration in patients with a chronic course of the disorder
clearly point to a progression of corresponding cerebral changes
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as demonstrated in a recent study from the Heidelberg group (29).
From a clinical perspective, NSS may therefore be used to identify
subjects at risk to develop chronic schizophrenia. It is well known,
that total NSS scores in schizophrenia are mainly due to motor
and sensory subscores. Unfortunately, only 7 of 17 studies (10–
12, 16, 17, 21, 25) reported subscores; therefore, a more detailed
meta-analysis could not be performed.
A decrease of NSS scores with clinical stabilization was also
reported in adolescent patients with FE psychosis (16, 17), i.e.,
during an age in which the motor and sensory systems are still
not entirely maturated. Both studies of the Mayoral group also
found a decrease of NSS in the control group over the 2-year-
study period and a higher score level in patients on comparison.
Authors attributed their findings to an overall developmental delay
caused by rather than a direct consequence of the disease.
Potentially confounding variables include different NSS rat-
ing scales and study designs. Although different, the various NSS
scales are comparable with regard to the majority of subscales
and sensitivity (27); moreover, the potential impact of the respec-
tive psychometric differences is at least partially addressed by the
longitudinal designs of the studies. Neuroleptic treatment was
standardized in 6 of the included 17 studies only. However, the
vast majority of studies discussed here report decreasing NSS in
patients treated with any neuroleptic compound. Furthermore, it
is known that NSS are not caused by neuroleptic medication (30,
31). In our study, a negative correlation between effect sizes and
length of follow-up period was identified. It is plausible that clin-
ical stabilization occurs in the beginning of the follow-up interval
leaving mostly non-remitting patients. As a result, effect sizes of
NSS decrease with length of inspected interval.
Along with this, Buchanan et al. (19) did not find meaningful
or even significant differences in chronic patients receiving either
clozapine or haloperidol while Schröder et al. (9) demonstrated a
decrease of NSS in FE patients who received a conventional neu-
roleptic. As discussed above, the timing of the first examination
may even have great importance, in particular as the exact starting
points were not defined in a number of studies. The decrease of
NSS was correlated with age, although this did not reach statisti-
cal significance. The meta-analysis of cross-sectional studies (28)
did not find NSS difference scores between patients and healthy
controls to be moderated by age when only studies with the NES
were entered into the meta-analysis. Although both findings cor-
respond with respect to the direction of change, the impact of age
and other potential moderators as sex and education, or cognitive
reserve (Urbanowitsch et al., submitted) on NSS needs to be fur-
ther analyzed. Against the background of a relatively small number
of studies included here, the respective methodological questions
call for a large multicenter longitudinal study in FE patients. Such
an endeavor would not only be suitable to dissect the decrease
of NSS in the clinical course confirmed in this meta-analysis but
could also serve to define the state and trait characteristics of NSS
more precisely. The potential impact of motor development could
be addressed in adolescent patients; moreover, neuroimaging stud-
ies could be designed to better understand the role of motor and
sensory cortical sites in schizophrenia.
From a clinical standpoint, the decrease of NSS with clinical
stabilization may be used to monitor disease progression or to
identify subjects with an increased liability toward schizophrenia
in general and more chronic, unfavorable courses in particular.
As a phenomenon, NSS point at the involvement of motor and
sensory cerebral sites in the disorder. Since NSS correspond to
impaired motor and sensory functions like motor coordination,
they can be used to further develop and optimize physical train-
ing programs, which are already part of the routine therapeutic
repertoire.
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